Publications by authors named "Alejandro D Ricart"

Claim this Profile
T
Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study.
Julio Peguero, Davendra P S Sohal, Bert H O'Neil, Howard Safran, Karen Kelly, Alejandro D Ricart

JCO Precis Oncol· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory Hodgkin lymphoma treated with brentuximab vedotin.
Changxia Shao, Jinan Liu, Wei Zhou, Monika K Raut, Matthew Monberg, Alejandro D Ricart

Leuk Lymphoma· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.
Robert Chen, Pier Luigi Zinzani, Michelle A Fanale, Philippe Armand, Nathalie A Johnson, Alejandro D Ricart

J Clin Oncol· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure.
Philippe Armand, Margaret A Shipp, Vincent Ribrag, Jean-Marie Michot, Pier Luigi Zinzani, Alejandro D Ricart

J Clin Oncol· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pharmacodynamically guided dose selection of PF-00337210 in a phase I study in patients with advanced solid tumors.
Justine Yang Bruce, Patricia M LoRusso, Priscila H Goncalves, Elisabeth I Heath, Elizabeth Sadowski, Alejandro D Ricart

Cancer Chemother Pharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).
Donghua Yin, Kerry B Barker, Ruifeng Li, Xu Meng, Steven D Reich, Alejandro D Ricart

Br J Clin Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New FDA breakthrough-drug category--implications for patients.
Alejandro D Ricart

N Engl J Med· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib or bevacizumab plus FOLFIRI or modified FOLFOX-6 after failure of first-line therapy for metastatic colorectal cancer: a randomized phase II study.
Johanna C Bendell, Christophe Tournigand, Anna Swieboda-Sadlej, Carlo Barone, Zev A Wainberg, Alejandro D Ricart

Clin Colorectal Cancer· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors.
Luis E Raez, Kyriakos Papadopoulos, Alejandro D Ricart, E Gabriella Chiorean, Robert S Dipaola

Cancer Chemother Pharmacol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of axitinib (AG-013736) in combination with gemcitabine in patients with advanced pancreatic cancer.
Jean-Philippe Spano, Malcolm J Moore, Yazdi K Pithavala, Alejandro D Ricart, Sinil Kim

Invest New Drugs· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I study of MN-029 (denibulin), a novel vascular-disrupting agent, in patients with advanced solid tumors.
Alejandro D Ricart, Edward A Ashton, Matthew M Cooney, John Sarantopoulos, Joanna M Brell

Cancer Chemother Pharmacol· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin.
Alejandro D Ricart

Clin Cancer Res· October 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pilot study of PD-0325901 in previously treated patients with advanced melanoma, breast cancer, and colon cancer.
Peter D Boasberg, Charles H Redfern, Gregory A Daniels, David Bodkin, Chris R Garrett, Alejandro D Ricart

Cancer Chemother Pharmacol· August 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
Brian I Rini, Joan H Schiller, John P Fruehauf, Ezra E W Cohen, Jamal C Tarazi, Alejandro D Ricart

Clin Cancer Res· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study.
Hedy L Kindler, Tatsuya Ioka, Dirk J Richel, Jaafar Bennouna, Richard Létourneau, Alejandro D Ricart

Lancet Oncol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
Monica Mita, Kevin R Kelly, Alain Mita, Alejandro D Ricart, Ofelia Romero

Clin Cancer Res· January 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II study of PD-0325901, an oral MEK inhibitor, in previously treated patients with advanced non-small cell lung cancer.
Eric B Haura, Alejandro D Ricart, Timothy G Larson, Philip J Stella, Lyudmila Bazhenova

Clin Cancer Res· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers.
Patricia M LoRusso, Smitha S Krishnamurthi, John J Rinehart, Lisle M Nabell, Lisa Malburg, Alejandro D Ricart

Clin Cancer Res· March 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Satraplatin, an oral platinum, administered on a five-day every-five-week schedule: a pharmacokinetic and food effect study.
Alejandro D Ricart, John Sarantopoulos, Emiliano Calvo, Quincy S Chu, Douglas Greene

Clin Cancer Res· June 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Volociximab, a chimeric monoclonal antibody that specifically binds alpha5beta1 integrin: a phase I, pharmacokinetic, and biological correlative study.
Alejandro D Ricart, Anthony W Tolcher, Glenn Liu, Kyle Holen, Garry Schwartz

Clin Cancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Alejandro D Ricart, Jordan D Berlin, Kyriakos P Papadopoulos, Samira Syed, Daniel W Drolet

Clin Cancer Res· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study.
Jean-Philippe Spano, Catherine Chodkiewicz, Joan Maurel, Ralph Wong, Harpreet Wasan, Alejandro D Ricart

Lancet· June 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
Monica M Mita, Alain C Mita, Quincy S Chu, Eric K Rowinsky, Gerald J Fetterly, Alejandro D Ricart

J Clin Oncol· January 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Technology insight: cytotoxic drug immunoconjugates for cancer therapy.
Alejandro D Ricart, Anthony W Tolcher

Nat Clin Pract Oncol· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Alejandro D Ricart, Lisa A Hammond, John G Kuhn, Chris H Takimoto, Andrew Goetz

Clin Cancer Res· December 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis